Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022.

It is well known that these subtypes are associated with high-rates of pathologic complete response (pCR), reaching 60 % in some studies [ 12 , [27] , [28] , [29] , [30] ], and that the latter is a highly significant prognostic marker for both disease-free survival and overall survival [ 13 ].

also in 132,142 other papers